Estrella Immunopharma FY26 Q2 net loss narrows 58.18% to $2.3 million

Reuters2026/08/13 21:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Estrella Immunopharma posted a GAAP net loss of USD 2.3 million for the three months ended June 30, 2026, narrowing from USD 5.5 million.
Research and development expense fell 69.9% to USD 1.4 million on timing of patient dosing milestones payable to Eureka.
General and administrative costs dropped 22.6% to USD 0.7 million on lower legal and professional fees.
For the six months ended June 30, 2026, net loss narrowed to USD 4.6 million from USD 7.6 million as R&D declined 53.9% to USD 2.8 million.
Cash and cash equivalents totaled USD 115,000 at June 30, 2026, with an USD 8.3 million accrued liability tied to STARLIGHT-1 dosing milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089215), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Estrella Immunopharma FY26 Q2 net loss narrows 58.18% to $2.3 million

You may also like

Crypto prices